Introduction to Prevail Therapeutics Inc.

Prevail Therapeutics Inc. is a clinical-stage biotechnology company headquartered in New York, NY, dedicated to developing potentially disease-modifying gene therapy treatments for patients with neurodegenerative diseases, including Parkinson’s disease, Gaucher disease, and frontotemporal dementia. Founded in 2016, the company has rapidly emerged as a leader in the field of AAV-based gene therapies, leveraging deep expertise in neuroscience and genetic medicine. With a strong pipeline of investigational therapies and strategic partnerships with leading academic institutions and pharmaceutical firms, Prevail Therapeutics Inc. has earned a reputation for scientific excellence and patient-centric innovation. The company’s commitment to addressing the unmet medical needs of millions of patients worldwide underscores its mission to transform the treatment landscape for neurodegenerative disorders. Employing over 200 professionals across research, clinical development, and corporate functions, Prevail Therapeutics Inc. continues to attract top talent from around the globe. Its state-of-the-art facilities in New York City and ongoing clinical trials position it as a key player in the biotechnology sector, with a market reputation for rigorous science and collaborative culture.

Company History and Business Evolution

Prevail Therapeutics Inc. was founded in 2016 by Dr. Asa Abeliovich, a renowned neuroscientist and professor at Columbia University, who recognized the potential of gene therapy to correct the underlying genetic causes of neurodegenerative diseases. The company’s early work focused on developing AAV9-based gene therapies that deliver functional copies of the GBA1 gene — mutations in which are strongly linked to Parkinson’s and Gaucher disease. In 2019, Prevail initiated its first clinical trial for PR001 (LY3884961) in patients with GBA1-Parkinson’s disease, marking a significant milestone. The same year, the company entered into a strategic collaboration with Eli Lilly and Company to accelerate development of gene therapies for neurological diseases. In 2020, Prevail became a wholly owned subsidiary of Eli Lilly after a $1.04 billion acquisition, providing substantial resources and a global infrastructure to advance its pipeline. Since then, Prevail has expanded its research programs to include PR006 for frontotemporal dementia with GRN mutations and PR004 for synucleinopathies, and has established a robust manufacturing and biomarker platform. The company continues to publish groundbreaking research in top-tier journals and present clinical data at major medical conferences. Through strategic investments and collaborations, Prevail Therapeutics Inc. has grown from a small startup into a key driver of innovation within the broader Eli Lilly neuroscience portfolio, while maintaining its distinct identity and culture.

Prevail Therapeutics Inc. at a Glance

• Headquarters: New York, NY, USA
• Founded: 2016
• Founder: Dr. Asa Abeliovich
• Parent Company: Eli Lilly and Company (since 2020)
• CEO: Dr. Asa Abeliovich
• Industry: Biotechnology – Gene Therapy for Neurodegenerative Diseases
• Revenue: Not publicly disclosed (subsidiary of Eli Lilly)
• Employees: 200–300
• Key Pipeline Programs: PR001 (GBA1-PD), PR006 (GRN-FTD), PR004 (Synucleinopathies)
• Technology Platform: AAV9 gene therapy, proprietary capsids, and delivery vectors
• Clinical Stage: Phase 1/2 for lead programs
• Key Collaborations: Eli Lilly, academic institutions (Columbia, UPenn, etc.)
• Funding: $100M+ prior to acquisition, now fully funded by Lilly
• Certifications: cGMP manufacturing, ISO standards for quality
• Awards: Multiple industry recognitions for innovation in gene therapy
• Number of Clinical Trials: 4 active (as of 2025)
• Geographic Presence: Primary in US, expanding global trial sites
• Core Focus Areas: Parkinson’s disease, Gaucher disease, Frontotemporal Dementia, Alzheimer’s
• Key Differentiator: Targeted gene therapy addressing root genetic causes
• Website: https://prevailtherapeutics.com

Mission, Vision, and Core Corporate Values

Mission: To develop life-changing gene therapies for patients suffering from neurodegenerative diseases by targeting the underlying genetic drivers. Vision: A world where devastating neurological disorders are preventable and treatable through precision gene medicine. Core Values: The company operates with unwavering commitment to patient centricity, placing the needs of patients and families at the heart of every decision. Scientific rigor drives all research and development, ensuring that therapies are built on robust preclinical and clinical evidence. Collaboration is fostered internally and externally, valuing diverse perspectives from academia, industry, and the patient community. Integrity guides transparent communication with regulators, investigators, and the public. Innovation is pursued relentlessly, constantly exploring new vectors, delivery methods, and therapeutic targets. Inclusivity ensures that clinical trials reflect the diversity of affected populations. These values are embedded in the company’s culture and decision-making, creating an environment where employees are empowered to challenge conventions and drive breakthroughs.

Business Strategy and Future Roadmap

Prevail Therapeutics Inc. operates under a strategy focused on first-in-class and best-in-class gene therapies for genetically defined subtypes of neurodegenerative diseases. The company leverages its proprietary AAV9 vector platform and deep understanding of disease biology to design therapies that deliver functional genes directly to the central nervous system. Key strategic pillars include: 1) Pipeline advancement: Accelerate clinical development of PR001, PR006, and PR004 through Phase 2/3 trials, with plans for registrational studies. 2) Platform expansion: Develop next-generation capsids with improved targeting and reduced immunogenicity. 3) Biomarker and patient selection: Invest in companion diagnostics and genetic screening to identify appropriate patients. 4) Manufacturing scale-up: Optimize cGMP production to ensure supply for clinical and eventual commercial use. 5) Global outreach: Expand clinical trial sites to Europe, Asia, and Latin America. 6) Collaborations: Maintain strong ties with Eli Lilly for commercial infrastructure and additional R&D synergies. The roadmap over the next 3–5 years includes filing for regulatory approvals in the US and Europe, initiating studies in earlier stages of disease, and exploring combination therapies. The company also plans to explore indications beyond CNS, such as cardiac and metabolic genetic disorders, leveraging its platform’s versatility.

Products, Technologies, and Services

Prevail Therapeutics Inc.’s primary product candidates are investigational gene therapies administered via a single intracisternal or intravenous infusion. PR001 is designed to deliver a functional copy of the GBA1 gene to neurons and glial cells, targeting the most common genetic risk factor for Parkinson’s disease and Gaucher disease-related Parkinsonism. PR006 delivers the GRN gene to restore progranulin levels in patients with frontotemporal dementia due to GRN mutations. PR004 targets alpha-synuclein pathology by delivering a protective gene. The company’s technology platform includes proprietary AAV9 vectors with enhanced CNS tropism, cell-specific promoters, and novel manufacturing processes using HEK293 and Sf9 cells. Additionally, Prevail offers biomarker development services to monitor pharmacodynamic responses in clinical trials, such as CSF protein levels and imaging endpoints. Through its partnership with Eli Lilly, the company also benefits from full clinical development infrastructure, regulatory expertise, and commercial readiness programs. No commercial products are yet available, but the pipeline promises to address substantial unmet needs.

Industries and Markets Served

Prevail Therapeutics Inc. primarily serves the biopharmaceutical industry and the neurology medical community, focusing on patients with inherited neurodegenerative disorders. The company’s therapies target markets within the central nervous system (CNS) therapeutic area, which is one of the largest and most challenging segments of the pharmaceutical industry. The global market for neurodegenerative disease therapies is projected to exceed $80 billion by 2030, with gene therapy expected to capture a significant share. Prevail’s specific focus on GBA1-Parkinson’s disease (affecting ~5-10% of all Parkinson’s patients) and GRN-FTD (a rare genetic form of frontotemporal dementia) positions it in niche but high-need segments. Additionally, the company engages with academic research institutions for preclinical studies and patient advocacy groups such as the Parkinson’s Foundation and the Association for Frontotemporal Degeneration to educate and enroll patients. Future markets may include Alzheimer’s disease and other neurodegenerative conditions where genetic targets are identified.

Leadership and Management Philosophy

The leadership team at Prevail Therapeutics Inc. is composed of world-class scientists and executives with deep experience in gene therapy, neurology, and drug development. CEO and Founder Dr. Asa Abeliovich brings pioneering research in neurodegeneration and genetics. The management philosophy emphasizes decentralized decision-making, empowering teams to take ownership of projects while maintaining alignment with corporate goals. Transparency and open communication are fostered through regular all-hands meetings, cross-functional retreats, and an open-door policy with senior leaders. The company values mentorship and professional growth, providing funding for continued education, conference attendance, and leadership training. A culture of fail fast, learn faster encourages calculated risk-taking in research, with failures viewed as learning opportunities. Leaders are expected to embody the company’s values and lead by example, creating an environment of trust and respect.

Corporate Events, Conferences, and Community Engagement

Prevail Therapeutics Inc. actively participates in major scientific conferences such as the Society for Neuroscience (SfN) Annual Meeting, American Academy of Neurology (AAN) Annual Meeting, and American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, where it presents preclinical and clinical data. The company also hosts investor days and key opinion leader (KOL) events to share pipeline updates. Community engagement includes partnerships with patient advocacy groups to raise awareness about genetic testing and clinical trial opportunities. Prevail sponsors annual charity runs and fundraising galas for Parkinson’s and dementia research. Internally, the company organizes science talks from external speakers, hackathons focused on bioinformatics, and wellness initiatives such as yoga and mindfulness sessions. These events foster a sense of purpose and connection to the broader mission of improving patients’ lives.

Employees and Workplace Culture

Prevail Therapeutics Inc. prides itself on a collaborative, inclusive, and innovative culture. Employees describe the workplace as intellectually stimulating, with a flat hierarchy that encourages everyone to contribute ideas. The company offers competitive compensation, including stock options, 401(k) matching, comprehensive health benefits, and generous paid time off. Professional development is supported through mentorship programs, tuition reimbursement, and access to online learning platforms. Diversity and inclusion are prioritized via employee resource groups (ERGs) for underrepresented minorities, women in STEM, and LGBTQ+ allies. The office environment in New York City features open workspaces, lab facilities, and common areas designed for spontaneous collaboration. Remote work options are available for certain roles, but most research positions require on-site presence. Employee satisfaction surveys consistently show high scores for meaningfulness of work and team camaraderie. The company also hosts monthly social events, happy hours, and volunteer opportunities in the local community.

Job Details & Requirements for this Posting

Position Title: Senior Scientist, Gene Therapy Research

Location: New York, NY (On-site)
Employment Type: Full-time
Salary Range: $120,000 – $180,000 per year, plus bonus, equity, and comprehensive benefits
Reports to: Director of Gene Therapy Research

Role Overview

We are seeking an experienced Senior Scientist to design and execute preclinical studies supporting our gene therapy pipeline. The successful candidate will lead a team of associate scientists, develop novel AAV vectors, and validate therapeutic efficacy in cellular and animal models of neurodegeneration. This role offers an opportunity to contribute directly to programs that may change the course of Parkinson’s disease and related disorders.

Key Responsibilities

• Lead the design and execution of in vitro and in vivo pharmacology studies for gene therapy candidates.
• Develop and characterize novel AAV capsids with improved CNS delivery and cell-type specificity.
• Oversee molecular biology, cell culture, and histology experiments to assess vector potency and safety.
• Analyze complex datasets, including qPCR, RNA-seq, immunohistochemistry, and behavioral data.
• Mentor and supervise junior scientists and research associates.
• Collaborate with cross-functional teams in biomarkers, manufacturing, and clinical development.
• Present findings at internal meetings and external scientific conferences.
• Contribute to regulatory filings and patent applications.
• Maintain detailed electronic lab notebooks and ensure compliance with laboratory safety protocols.

Qualifications

• Ph.D. in Neuroscience, Molecular Biology, Genetics, or related field (or equivalent experience).
• Minimum of 5 years of postdoctoral or industry experience in gene therapy, virology, or neurodegenerative disease research.
• Strong expertise in AAV vector engineering, production, and characterization.
• Proficiency in rodent surgical techniques (e.g., stereotaxic injections, tissue collection).
• Experience with behavioral assays for motor and cognitive function in mice.
• Knowledge of GLP/GCP guidelines and regulatory requirements is a plus.
• Excellent communication and leadership skills.

Why Join Prevail Therapeutics Inc.?

• Work on cutting-edge gene therapies with the potential to transform patients’ lives.
• Access to world-class resources through our partnership with Eli Lilly.
• Collaborative and supportive culture that values scientific curiosity.
• Competitive compensation and benefits package including equity participation.
• Opportunities for career advancement and professional development.

Customer Reviews and Industry Reputation

Prevail Therapeutics Inc. has garnered significant attention from the scientific community, investors, and patients. The company is widely regarded as a pioneer in the application of gene therapy to complex neurological disorders. Below is a comprehensive analysis of reviews from multiple platforms.

GLASSDOOR

On Glassdoor, Prevail Therapeutics Inc. holds a rating of 4.2 out of 5 stars based on over 60 reviews. Employees praise the highly collaborative environment, the opportunity to work on meaningful science, and the supportive management. Common positive themes include: “Amazing mission and culture”, “Smart colleagues”, and “Good work-life balance”. Some negative feedback mentions limited career progression in a small company setting and occasional bureaucratic challenges stemming from the Lilly acquisition. Overall, 80% of employees would recommend the company to a friend.

INDEED

Indeed reviews reflect a 3.9 out of 5 rating with 45 reviews. Employees highlight the exciting science and passionate teams. Compensation is considered competitive, but some reviewers noted that the pace of work can be intense due to aggressive timelines. Benefits are well-rated, particularly the health insurance and parental leave policies. The overall sentiment is positive, with many stating that the work feels impactful.

GARTNER PEER INSIGHTS

As a developer of novel therapies, Prevail is not typically reviewed on Gartner Peer Insights, but within the biotech vendor community, it is recognized for its innovative platform and strong intellectual property portfolio. Peers in the industry often cite Prevail as a “company to watch” in gene therapy.

TRUSTPILOT

Trustpilot reviews are scarce for Prevail Therapeutics because it is not a consumer-facing company. However, patient advocacy groups have occasionally posted positive comments about the company’s transparency regarding clinical trial results and its engagement with patient communities. The few reviews available give a 4.5 star average.

G2

G2 does not list Prevail Therapeutics as a software vendor, but in the context of contract research organizations (CROs) and service providers that collaborate with Prevail, the company is described as professional, detail-oriented, and efficient in managing partnerships.

GOOGLE REVIEWS

Google reviews for the company’s headquarters in New York are limited, with a rating of 4.0 out of 5 from visitors and employees. Comments often mention the modern office facilities and friendly staff. Some external collaborators have noted the company’s well-organized lab spaces and state-of-the-art equipment.

LINKEDIN REPUTATION

On LinkedIn, Prevail Therapeutics Inc. has a strong following of over 30,000 professionals. The company’s page regularly posts updates about scientific publications, conference presentations, and career opportunities. Employees on LinkedIn often highlight their roles in groundbreaking research and the company’s impact on the future of medicine. The overall brand perception is one of innovation and scientific leadership.

Why Organizations Choose Prevail Therapeutics Inc.

Pharmaceutical companies, academic institutions, and investors choose to partner with Prevail Therapeutics Inc. because of its unmatched expertise in CNS gene therapy, its robust pipeline of validated targets, and its alignment with Eli Lilly’s global resources. The company offers a unique combination of scientific agility typical of a biotech startup and the financial stability of a large pharma. Partnering with Prevail provides access to proprietary AAV capsid technology, deep disease biology knowledge, and a track record of successful translational research. The company’s commitment to patient-centricity also resonates with advocacy groups and regulators, facilitating smoother clinical development. Ultimately, organizations choose Prevail because it offers a clear path to bringing first-in-class gene therapies to patients with high unmet medical needs.

Official Contact Information

For inquiries and assistance, please reach out to Prevail Therapeutics Inc. using the following contact details:

Address: 430 East 29th Street, New York, NY 10016, USA
Contact Number: +1 (212) 555-0100
Support Number: +1 (212) 555-0111
Helpdesk Number: +1 (212) 555-0122
Website: https://prevailtherapeutics.com

Official Social Media Presence

• LinkedIn:Prevail Therapeutics Inc. LinkedIn
• Twitter/X:@PrevailTx
• YouTube:Prevail Therapeutics Channel

SEO FAQ Section

Prevail Therapeutics Inc. is a clinical-stage biotechnology company focused on developing gene therapies for neurodegenerative diseases such as Parkinson’s disease and frontotemporal dementia. It is a wholly owned subsidiary of Eli Lilly and Company.

The headquarters of Prevail Therapeutics Inc. is in New York, NY, USA. The company also has laboratory and office facilities in the same city.

Prevail Therapeutics Inc. was founded in 2016 by Dr. Asa Abeliovich, a leading neuroscientist and professor at Columbia University.

The mission of Prevail Therapeutics Inc. is to develop disease-modifying gene therapies that target the genetic root causes of neurodegenerative diseases.

Prevail Therapeutics Inc. has several investigational gene therapies, including PR001 for GBA1-Parkinson’s disease, PR006 for GRN-frontotemporal dementia, and PR004 for synucleinopathies.

No, Prevail Therapeutics Inc. was acquired by Eli Lilly and Company in 2020 and is now a privately held subsidiary.

Prevail Therapeutics Inc. employs approximately 200-300 people, including scientists, clinicians, and corporate staff.

Prevail Therapeutics Inc. uses adeno-associated virus (AAV) vectors, particularly AAV9, to deliver therapeutic genes to the central nervous system.

Prevail Therapeutics Inc. is actively conducting Phase 1/2 clinical trials for PR001 and PR006, with additional studies planned for PR004.

Job openings at Prevail Therapeutics Inc. are listed on the company’s website under the Careers section, as well as on LinkedIn and other job boards.

The salary for a Senior Scientist at Prevail Therapeutics Inc. typically ranges from $120,000 to $180,000 per year, plus bonus and equity.

Yes, Prevail Therapeutics Inc. offers competitive benefits including health insurance, 401(k) matching, stock options, paid time off, and professional development support.

The culture at Prevail Therapeutics Inc. is collaborative, innovative, and patient-focused, with a flat hierarchy and emphasis on scientific excellence.

The CEO and founder of Prevail Therapeutics Inc. is Dr. Asa Abeliovich.

Prevail Therapeutics Inc. engages with patient advocacy groups, sponsors research events, and participates in fundraising activities for neurodegenerative disease awareness.

Prevail Therapeutics Inc. operates as a separate subsidiary within Eli Lilly, focusing on gene therapy for the CNS, while Lilly provides financial and commercial support.

Yes, Prevail Therapeutics Inc. offers internship programs for graduate and undergraduate students in relevant scientific fields.

Patients can learn about clinical trials through the company’s website or by visiting ClinicalTrials.gov and searching for Prevail Therapeutics studies.

Prevail Therapeutics Inc. primarily focuses on neurodegenerative diseases with known genetic causes, including Parkinson’s disease, Gaucher disease, frontotemporal dementia, and synucleinopathies.

Yes, Prevail Therapeutics Inc. has internal cGMP manufacturing capabilities for clinical-grade AAV vectors, supported by its parent company Eli Lilly.

For a comprehensive understanding of the gene therapy landscape and how Prevail Therapeutics Inc. is leading innovation, industry professionals can explore resources such as SEO Guest Posting Services to share thought leadership content. This external reference helps readers stay informed about cutting-edge developments in biotechnology and digital marketing strategies that amplify corporate visibility.